Portfoliotracker

Yarrow Bioscience, Inc.

YARW · NASDAQCM · Healthcare Biotechnology

13,93 $
▼ −4,10 (−22,74 %)
Pre-market delayed by 15 min
Price as of 16. 11. 22:00, fetched 17. 11. 14:03
Next earnings–
Ex-dividend–
Analysts–
50 / 200 day average– / –

Price

Portfoliotracker score– Market cap12,0 mil. $ P/E– Forward P/E-8,9 P/S25,1 P/B0,5 EV/EBITDA– Dividend yield144,29 % FCF yield– EPS– Net margin0,0 % Return on equity– Beta2,13 Debt / equity–
52-week range 12,39 to 46,95
3-month average volume0,1 M

Finance

Where the revenue goes

Loading the income statement flow…

Fundamentals

Loading key figures…

Insiders, analysts and people

All trades and changes

Loading insiders, analysts and opinions…

Co se právě děje

AI souhrn
Objednat AI souhrn, co se u firmy právě děje Vytvoří se jednou na pozadí a pak ho uvidí všichni. Ve verzi Free 3 objednávky měsíčně.

About the company

Yarrow Bioscience, Inc. operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases. The company's candidate, YB-101, is a humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor (TSHR) for the treatment of Graves' disease and thyroid eye disease. The company was incorporated in 2025 and is based in New York, New York.

Employees
7
Country
United States
Fiscal year end
31. 12.
Data since
25. 1. 2018

Explore further

Similar companies ODTXTRAXCOAGMAZETECX

Intraday chart

Your own portfolio, properties and finances in one place.

The account is free with no time limit. Only you see your data; nobody adds it up with others.

This is saved to your account. You can keep browsing, calculating and comparing without signing in.

Welcome back

Sign in and pick up where you left off.

or continue with

No account yet? Create a free account